AP804A - APO-B-secretion/MTP inhibitory amides. - Google Patents

APO-B-secretion/MTP inhibitory amides. Download PDF

Info

Publication number
AP804A
AP804A APAP/P/1997/001145A AP9701145A AP804A AP 804 A AP804 A AP 804A AP 9701145 A AP9701145 A AP 9701145A AP 804 A AP804 A AP 804A
Authority
AP
ARIPO
Prior art keywords
inhibitors
compounds
crc10
alkyl
crc4
Prior art date
Application number
APAP/P/1997/001145A
Other languages
English (en)
Other versions
AP9701145A0 (en
Inventor
George Chang
George J Quallich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701145A0 publication Critical patent/AP9701145A0/xx
Application granted granted Critical
Publication of AP804A publication Critical patent/AP804A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
APAP/P/1997/001145A 1996-11-27 1997-11-20 APO-B-secretion/MTP inhibitory amides. AP804A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3230796P 1996-11-27 1996-11-27
PCT/IB1997/001368 WO1998023593A1 (en) 1996-11-27 1997-11-03 Apo b-secretion/mtp inhibitory amides

Publications (2)

Publication Number Publication Date
AP9701145A0 AP9701145A0 (en) 1998-01-31
AP804A true AP804A (en) 2000-01-28

Family

ID=21864233

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001145A AP804A (en) 1996-11-27 1997-11-20 APO-B-secretion/MTP inhibitory amides.

Country Status (34)

Country Link
US (1) US6121283A (id)
EP (1) EP0944602A1 (id)
JP (1) JP3270764B2 (id)
KR (1) KR100334567B1 (id)
CN (2) CN1238764A (id)
AP (1) AP804A (id)
AR (1) AR010309A1 (id)
AU (1) AU716151B2 (id)
BG (2) BG108830A (id)
BR (1) BR9714364A (id)
CA (1) CA2272719C (id)
CZ (1) CZ292160B6 (id)
DZ (1) DZ2358A1 (id)
EA (1) EA001539B1 (id)
GT (1) GT199700122A (id)
HN (1) HN1997000144A (id)
HR (1) HRP970642A2 (id)
ID (1) ID18995A (id)
IL (1) IL129744A0 (id)
IS (1) IS5040A (id)
MA (1) MA26451A1 (id)
NO (1) NO312760B1 (id)
NZ (1) NZ335162A (id)
OA (1) OA11050A (id)
PA (1) PA8441601A1 (id)
PE (1) PE17199A1 (id)
SK (1) SK65499A3 (id)
TN (1) TNSN97193A1 (id)
TR (1) TR199901180T2 (id)
TW (1) TW502023B (id)
UY (1) UY24789A1 (id)
WO (1) WO1998023593A1 (id)
YU (1) YU23499A (id)
ZA (1) ZA9710641B (id)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
MX9709914A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
IL142388A0 (en) 1998-10-08 2002-03-10 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
PT1140187E (pt) * 1998-12-23 2004-01-30 Searle Llc Combinacoes de um inibidor de ibat e de um inibidor de mtp para indicacoes cardiovasculares
WO2000038726A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
AU6824700A (en) * 1999-07-20 2001-02-05 Novartis Ag Organic compounds
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
IL139449A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
CA2324800A1 (en) * 1999-11-10 2001-05-10 Mary Anne Hickman Use of apo b secretion/mtp inhibitors
EP1259484B1 (en) 2000-01-18 2005-05-18 Novartis AG Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
AU2001260113B2 (en) * 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2001077077A1 (en) * 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AU2001277728A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
AU2001277727A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
KR20030029871A (ko) * 2000-09-01 2003-04-16 상꾜 가부시키가이샤 의약 조성물
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
WO2002028835A1 (en) * 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
WO2002090347A1 (en) * 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
PL367680A1 (en) 2001-06-28 2005-03-07 Pfizer Products Inc. Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
US20030130343A1 (en) * 2001-08-10 2003-07-10 Adipogenix, Inc. Fat accumulation-modulating compounds
WO2003045921A1 (en) * 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
CN101838218A (zh) * 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
WO2003077874A2 (en) * 2002-03-13 2003-09-25 The University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
BR0317426A (pt) * 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicéridos microssomais
WO2004056777A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
CA2519458A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
WO2005021486A1 (ja) * 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP1806149A4 (en) * 2004-10-25 2012-12-05 Japan Tobacco Inc SOLID MEDICINAL PREPARATION IMPROVED IN TERMS OF SOLUBILITY AND STABILITY AND METHOD FOR PRODUCING SAME
EP1843819A2 (en) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
MX2007005137A (es) 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
NZ563009A (en) 2005-04-19 2011-05-27 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
PL2666859T3 (pl) * 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
EP2037929A4 (en) * 2006-06-02 2010-02-17 Univ San Diego State Res Found COMPOSITIONS AND METHODS FOR REDUCING HYPERLIPIDEMIA
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
CA2666191C (en) * 2006-10-09 2017-07-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
DE602007006833D1 (de) 2006-10-24 2010-07-08 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1-carbonsäurederivate
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008075949A1 (en) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
EP2126079A1 (en) * 2007-03-22 2009-12-02 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
WO2009003003A2 (en) * 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
EP2225261B1 (en) 2007-12-03 2016-03-09 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
WO2015065595A1 (en) 2013-10-30 2015-05-07 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP2018502900A (ja) * 2014-10-22 2018-02-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CN117062812A (zh) * 2021-03-26 2023-11-14 奇斯药制品公司 作为ddr抑制剂的吲哚啉衍生物
AU2022246108A1 (en) * 2021-03-26 2023-11-09 Chiesi Farmaceutici S.P.A. Indoline derivatives as ddr1 and ddr2 inhibitors
CN113292493A (zh) * 2021-06-23 2021-08-24 上海立科化学科技有限公司 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
WO2024216197A2 (en) * 2023-04-13 2024-10-17 Acelot, Inc. Compounds and methods for treating protein aggregation diseases
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0643057A1 (en) * 1993-09-03 1995-03-15 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein
WO1996026205A1 (en) * 1995-02-21 1996-08-29 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0643057A1 (en) * 1993-09-03 1995-03-15 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein
WO1996026205A1 (en) * 1995-02-21 1996-08-29 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
ID18995A (id) 1998-05-28
EA199900416A1 (ru) 1999-12-29
IS5040A (is) 1999-04-30
KR20000057269A (ko) 2000-09-15
CA2272719A1 (en) 1998-06-04
BG108830A (bg) 2005-10-31
EA001539B1 (ru) 2001-04-23
BG103434A (en) 2000-07-31
AP9701145A0 (en) 1998-01-31
DZ2358A1 (fr) 2002-12-28
CA2272719C (en) 2002-10-01
NZ335162A (en) 2000-01-28
CN1380289A (zh) 2002-11-20
OA11050A (en) 2002-03-07
HRP970642A2 (en) 1998-10-31
CN1238764A (zh) 1999-12-15
BR9714364A (pt) 2000-03-21
CZ292160B6 (cs) 2003-08-13
TNSN97193A1 (fr) 2005-03-15
US6121283A (en) 2000-09-19
TW502023B (en) 2002-09-11
AR010309A1 (es) 2000-06-07
KR100334567B1 (ko) 2002-05-03
NO992525L (no) 1999-05-26
IL129744A0 (en) 2000-02-29
JP3270764B2 (ja) 2002-04-02
SK65499A3 (en) 2001-05-10
AU716151B2 (en) 2000-02-17
JP2000505810A (ja) 2000-05-16
GT199700122A (es) 1999-05-19
ZA9710641B (en) 1999-05-26
NO992525D0 (no) 1999-05-26
PE17199A1 (es) 1999-02-19
MA26451A1 (fr) 2004-12-20
PA8441601A1 (es) 2000-05-24
HN1997000144A (es) 1997-12-16
YU23499A (sh) 2001-07-10
EP0944602A1 (en) 1999-09-29
TR199901180T2 (xx) 1999-08-23
NO312760B1 (no) 2002-07-01
WO1998023593A1 (en) 1998-06-04
UY24789A1 (es) 2000-09-29
AU4634797A (en) 1998-06-22

Similar Documents

Publication Publication Date Title
AP804A (en) APO-B-secretion/MTP inhibitory amides.
US6121304A (en) Pentafluorobenzenesulfonamides and analogs
ES2754221T3 (es) Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo
RU2618628C1 (ru) Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
US7291644B2 (en) Indole derivatives
EP2593428B1 (en) N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP5989923B2 (ja) メチル基変更酵素の調節物質、組成物及びその使用
McKew et al. Indole Cytosolic Phospholipase A2 α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3, 4-dichlorobenzyl) sulfonyl] amino} ethyl)-1-(diphenylmethyl)-1 H-indol-3-yl] propyl} benzoic Acid, Efipladib
AU2015219920B2 (en) Triazine compound and use thereof for medical purposes
PT2004607E (pt) Derivados de ácido (4-(4-[6-(trifluorometil-piridin-3- -ilamino)-heteroaril contendo n]-fenil)-ciclo-hexil)- -acético e seus usos farmacêuticos
WO2010125831A1 (en) Sulfamoyl benzoic acid derivatives as trpm8 antagonists
KR20200015888A (ko) Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체
NZ532080A (en) Heterocyclic compounds and methods of use
JP2009513523A (ja) ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
EA016345B1 (ru) Новые сульфонилпирролы в качестве ингибиторов гдац (гистондезацетилазы)
CA3000431A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
US12258308B2 (en) Benzene derivative
US7135495B2 (en) Indole derivatives
Gribble et al. ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme
He et al. Design, synthesis and molecular docking of amide and urea derivatives as Escherichia coli PDHc-E1 inhibitors
US20160102074A1 (en) Substituted amide compounds
KR102860768B1 (ko) 신장 장애 치료에 사용하기 위한 화합물
Yang et al. Discovery of Novel N-Hydroxy-1, 2, 4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis
CN1227008C (zh) 将非cox－2选择性抑制剂的cox抑制化合物转化成为cox－2选择性抑制剂的衍生物的方法
Takahashi et al. Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid